Search Results - "Coates, L.C."

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation by Coates, L.C., Murphy, R., Helliwell, P.S.

Get full text

Comparison of screening questionnaires to identify psoriatic arthritis in a primary-care population: a cross-sectional study by Coates, L.C., Savage, L., Waxman, R., Moverley, A.R., Worthington, S., Helliwell, P.S.

“…Summary Background Many questionnaires are available for assessment of psoriatic arthritis (PsA), but there is little evidence comparing them. Objectives To…”
Get full text

PBI6 Stringent Thresholds of Disease Control Are Associated with Reduced Burden on Paid and Household Work Productivity in Patients with Psoriatic Arthritis during LONG-TERM Treatment with Certolizumab Pegol by Tillett, W., Coates, L.C., Nurminen, T., Kiri, S., Mease, P.

Get full text

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update by Smith, C.H., Yiu, Z.Z.N., Bale, T., Burden, A.D., Coates, L.C., Edwards, W., MacMahon, E., Mahil, S.K., McGuire, A., Murphy, R., Nelson‐Piercy, C., Owen, C.M., Parslew, R., Uthman, O.A., Woolf, R.T., Manounah, L., Ezejimofor, M.C., Exton, L.S., Mohd Mustapa, M.F.

“…Linked Comment: Ormerod. Br J Dermatol 2020; 183:604. Plain language summary available online…”
Get full text

Long‐term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease by Reich, K., Warren, R.B., Coates, L.C., Di Comite, G.

“…Psoriatic disease is a multifaceted disorder, which develops in the skin, its appendages and joints. Though characterized by different pathogenic background…”
Get full text

PCR65 Psychometric Assessment of the Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Questionnaire Using Pooled Data from the Phase 3 BE OPTIMAL and BE COMPLETE Trials of Bimekizumab in Patients with Psoriatic Arthritis by Gossec, L., Coates, L.C., Orbai, A.M., Pelligra, C., Lambert, J., Ciaravino, V., Ink, B., Taieb, V., Gladman, D.D.

Get full text

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 by Smith, C.H., Jabbar‐Lopez, Z.K., Yiu, Z.Z., Bale, T., Burden, A.D., Coates, L.C., Cruickshank, M., Hadoke, T., MacMahon, E., Murphy, R., Nelson‐Piercy, C., Owen, C.M., Parslew, R., Peleva, E., Pottinger, E., Samarasekera, E.J., Stoddart, J., Strudwicke, C., Venning, V. A., Warren, R.B., Exton, L.S., Mohd Mustapa, M.F.

“…Plain language summary available online…”
Get full text

PCR229 Achieving Increasingly Stringent Disease Control Criteria Was Associated with Greater Quality of Life Improvements in Patients with Active Psoriatic Arthritis: Results from BE OPTIMAL and BE COMPLETE/BE VITAL up to 1 Year by Kristensen, L.E., Coates, L.C., Mease, P.J., Merola, J.F., Gisondi, P., Nash, P., Ogdie, A.R., Tillett, W., Ink, B., Bajracharya, R., Taieb, V., Lambert, J., Willems, D., Walsh, J.A.

Get full text

SA64 Comparative Effectiveness of Bimekizumab in Patients with Psoriatic Arthritis: Results from a Systematic Literature Review and Network Meta-Analysis by Mease, P.J, Gladman, D.D., Merola, J.F, Nash, P., Grieve, S., Laliman-Khara, V., Willems, D., Taieb, V., Prickett, A.R, Coates, L.C

Get full text

Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta‐analysis by Mahil, S.K., Ezejimofor, M.C., Exton, L.S., Manounah, L., Burden, A.D., Coates, L.C., Brito, M., McGuire, A., Murphy, R., Owen, C.M., Parslew, R., Woolf, R.T., Yiu, Z.Z.N., Uthman, O.A., Mohd Mustapa, M.F., Smith, C.H.

“…Summary Background The rapid expansion of psoriasis biologics has led to an urgent need to understand their relative efficacy and tolerability to inform…”
Get full text

Psoriasis flare with corticosteroid use in psoriatic arthritis by Coates, L.C., Helliwell, P.S.

“…Plain language summary available online…”
Get full text

Patient education and screening for psoriatic arthritis is key in the care of patients with psoriasis, whichever method is chosen by Coates, L.C.

“…Linked Article: Mishra et al. Br J Dermatol 2017; 176:765–770…”
Get full text

Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study) by Coates, L.C., Aslam, T., Al Balushi, F., Burden, A.D., Burden-The, E., Caperon, A.R., Cerio, R., Chattopadhyay, C., Chinoy, H., Goodfield, M.J.D., Kay, L., Kelly, S., Kirkham, B.W., Lovell, C.R., Marzo-Ortega, H., McHugh, N., Murphy, R., Reynolds, N.J., Smith, C.H., Stewart, E.J.C., Warren, R.B., Waxman, R., Wilson, H.E., Helliwell, P.S.

“…Summary Background  Multiple questionnaires to screen for psoriatic arthritis (PsA) have been developed but the optimal screening questionnaire is unknown…”
Get full text

Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis by Coates, L.C., Savage, L.J., Chinoy, H., Laws, P.M., Lovell, C.R., Korendowych, E., Mahmood, F., Mathieson, H.R., McGonagle, D., Warren, R.B., Waxman, R., Helliwell, P.S.

“…Background Many patients with psoriasis have undiagnosed psoriatic arthritis. Low specificity is found with many PsA screening tools. A new instrument, the…”
Get full text

Usage of C-Reactive Protein Testing in the Diagnosis and Monitoring of Psoriatic Arthritis (PsA): Results from a Real-World Survey in the USA and Europe by Ogdie, A., Tillett, W., Booth, N., Howell, O., Schubert, A., Peterson, S., Chakravarty, S. D., Coates, L. C.

“…Introduction C-reactive protein (CRP) is an important non-specific marker of both acute and chronic inflammation and can be elevated in patients with psoriatic…”
Get full text

L’aprémilast améliore l’état des patients atteints du rhumatisme psoriasique de forme oligoarticulaire : analyse principale de l’essai thérapeutique contrôlé vs placebo FOREMOST by Gossec, L., Gladman, D., Coates, L.C., Aelion, J., Vasandani, J., Reddy, J., Wang, R., Brunori, M., Colgan, S., Mease, P.J.

Get full text

Impact du bimékizumab sur les domaines évalués par le GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) chez les patients atteints de rhumatisme psoriasique (RhPso) : résultats à 52 semaines issus de 4 études de phase III by Gossec, L., Merola, J.F., Mease, P.J., Deodhar, A., Ink, B., Fleurinck, C., Bajracharya, R., Coarse, J., Coates, L.C.

Get full text

Différences selon le sexe sur les perceptions de l’impact du rhumatisme psoriasique, sa gestion et les interactions avec les médecins : résultats d’une enquête internationale auprès des patients by Eder, L., Richette, P., Coates, L.C., Azevedo, V.F., Cappelleri, J.C., Hoang, M., Moser, J., Kinch, C., Kessouri, M.

Get full text

L’atteinte de critères cliniques plus stricts est associée à de plus importantes améliorations des critères patients (fonction physique, douleur) chez les patients atteints de rhumatisme psoriasique actif : résultats à 16 semaines de 2 études de phase III by Goupille, P., Walsh, J.A., Coates, L.C., Mease, P.J., Merola, J.F., Nash, P., Ogdie, A.R., Tillett, W., Gisondi, P., Ink, B., Assudani, D., Bajracharya, R., Lambert, J., Taieb, V., Willems, D., Kristensen, L.E.

“…Examiner l’association entre l’atteinte de critères cliniques de plus en plus stricts et les critères patients de la fonction physique et de la douleur chez…”
Get full text

Le bimékizumab chez des patients atteints de rhumatisme psoriasique et naïfs de biologique : évaluation de l’efficacité et de la tolérance à 24 semaines dans une étude de phase III by Gossec, L., McInnes, I.B., Coates, L.C., Landewé, R.B., Mease, P.J., Ritchlin, C.T., Tanaka, Y., Asahina, A., Gottlieb, A.B., Warren, R.B., Ink, B., Assudani, D., Coarse, J., Bajracharya, R., Merola, J.F.

“…L’étude pivot de phase III, BE OPTIMAL, a évalué l’efficacité et la tolérance du bimékizumab (BKZ), un anticorps monoclonal de type IgG1 qui inhibe de manière…”
Get full text